In a cohort of 115 EGFR exon 20 insertion NSCLC patients (median of two prior lines of therapy) only a limited RR of 14.8% and median PFS of 4.2 months was reported [52]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.